Becton Dickinson Infusion Therapy Systems, Inc. · Class II · Cleared Oct 8, 2025
| K-number | K251422 |
| Device name | BD Saf-T-Intima Subcutaneous Catheter System |
| Applicant | Becton Dickinson Infusion Therapy Systems, Inc. |
| Product code | FOZ |
| Device class | Class II |
| Decision date | Oct 8, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 880.5200 |
The BD Saf-T-Intima™ Subcutaneous Catheter System is an over-the-needle catheter designed for short-term use to administer fluids and medications into a patient's subcutaneous tissue, or to administer fluids and sample blood from the peripheral venous system. The device includes a radiopaque polyurethane catheter, needle with wire stylet, wings for insertion, integrated extension tubing with single or dual ports, a clamp, PRN adapter, and passive needle safety protection.
The subject device is a single-lumen winged polyurethane IV or subcutaneous catheter with integrated extension set and either single port (straight with PRN adapter) or dual port (Y-connection with PRN adapter and vent plug). It offers catheter sizes of 22 GA and 24 GA with 0.75-inch length, compared to the predicate's 18-24 GA with 0.75-1.00 inch lengths. The wings and extension tubing use PVC with DOA (non-DEHP) plasticizer instead of DEHP, meeting the same physical property and performance criteria.
ISO 80369-7, ISO 10555-1, ISO 10555-7, ISO 23908, ISO 11607, ISO 10993-1, ISO 11135-1; plus internal studies on peak insertion force, catheter drag force, stylet/needle removal force, and decouple force (safety shield); usability testing per FDA's February 2016 human factors guidance.
The subject device is substantially equivalent to the predicate BD Saf-T-Intima™ Intravascular Catheter (K013800) because both use the same fundamental single-lumen winged polyurethane technology with integrated extension tubing and similar operational principles. Differences in indications (expanded to include subcutaneous access, narrowed intravenous use to fluids/blood only, excluding pressure monitoring) and reduced catheter size options do not raise new safety or effectiveness concerns and are supported by comprehensive performance testing demonstrating compliance with design requirements.
View the full FDA submission: accessdata.fda.gov